RET and cancer: Further, we showed that the constitutive phosphorylation of RET, AKT, ERK, and S6 in TMEM127-KO cells could be blocked by RET inhibition using the multikinase inhibitor vandetanib, and selective RET inhibitors selpercatinib and pralsetinib (Figure 8C), which are clinically approved for the treatment of RET-associated cancers (Mulligan, 2018).